Results from the phase 3 IMMhance study show that of patients who reached sPGA 0 at week 28, 73% maintained skin clearance at week 94.
Long-term results from the phase 3 IMMhance study of risankizumab (Skyrizi) in patients with psoriasis indicated that a significant number of patients receiving risankizumab maintained complete skin clearance at week 94.
“Results show that Skyrizi has the potential to provide long-term relief from the signs and symptoms of psoriasis,” said Marek Honczarenko, MD, PhD, vice president, immunology development, AbbVie.
In this study, patients who reached a score of clear or almost clear on the static Physician Global Assessment (sPGA 0/1) at week 28 were randomized to either continue on risankizumab or placebo. Of those with continuous treatment with risankizumab, 73% achieved a sPGA of 0 and 72% reached a 100% improvement in the Psoriasis Area and Severity Index (PASI 100).
In comparison, just 2% of patients randomized to withdrawal from risankizumab via placebo experienced complete skin clearance (P <.001).
“In the IMMhance study, Skyrizi provided an increasing number of patients with complete skin clearance up to 94 weeks,” said Melinda Gooderham, MD, dermatologist and medical director at the SKiN Centre for Dermatology in Peterborough, Ontario and a study investigator.
|Read on: [wp_colorbox_media url=”https://www.mdmag.com/medical-news/risankizumab-provides-longterm-psoriasis-skin-clearance” type=”iframe” hyperlink=”Risankizumab Provides Long-term Psoriasis Skin Clearance”]|